Strides Pharma Science has announced a strategic product development partnership with Kenox Pharmaceuticals Inc., aimed at expanding its nasal spray product range for the U.S. market. This collaboration marks a significant step in Strides' efforts to strengthen its presence in the American pharmaceutical landscape, particularly in the growing nasal spray segment.

Partnership Details

The agreement, signed by Strides Pharma Global Pte. Limited, Singapore, a step-down wholly owned subsidiary of Strides, focuses on the development and filing of multiple nasal spray products across diverse therapeutic indications for the U.S. market. While specific product details remain confidential, the partnership leverages Kenox's expertise in Orally Inhaled and Nasal Drug Products (OINDPs) to complement Strides' manufacturing and market presence.

Strategic Significance

Aditya Kumar, Executive Director Business Development at Strides Pharma Science Limited, emphasized the importance of this collaboration, stating, "Nasal sprays have consistently been highlighted as a key focus area for Strides, and this collaboration further builds on the solid progress we have already made in this domain." He added that the partnership aligns well with Strides' ongoing investments in capabilities and capacities at their U.S. facility.

Expertise Synergy

The partnership brings together Strides' commercial strengths and Kenox's formulation and development expertise in the OINDP space. Dr. Sitaram Velaga, Founder, President and CEO of Kenox Pharmaceuticals Inc., expressed enthusiasm about the collaboration, noting that it "validates our expertise in the OINDP space and will allow us to leverage our capabilities to bring important drug products to global patients at an affordable price."

Market Impact

This strategic move is expected to accelerate Strides' range of nasal spray offerings in the U.S. market. By combining Strides' commercial prowess with Kenox's specialized knowledge, the partnership aims to deliver affordable, high-quality therapies to patients, potentially expanding Strides' market share in the competitive U.S. pharmaceutical landscape.

About the Companies

Strides Pharma Science Ltd is a global pharmaceutical company headquartered in Bengaluru, India, with a focus on "difficult to manufacture" products sold in over 100 countries. The company operates primarily in regulated markets and has manufacturing sites in India, Italy, Kenya, and the United States.

Kenox Pharmaceuticals Inc., established in 2018 and based in greater Princeton, NJ, specializes in pharmaceutical aerosol product development, including soft mist inhalers, dry powder inhalers, nebulizers, and nasal sprays.

As both companies look to capitalize on their respective strengths, this collaboration could potentially reshape the nasal spray market in the United States, offering new and innovative solutions to meet patient needs.

Strides Pharma Science Limited , a prominent player in the pharmaceutical industry, has taken a strategic step towards optimizing its global operations. The company announced the voluntary deregistration of its non-operating step-down subsidiary, Apollo Life Sciences Holdings (Pty) Ltd, in South Africa, effective August 22, 2025.

Streamlining Group Entities

The deregistration is part of Strides Pharma's ongoing efforts to streamline its group entities and eliminate non-operating companies. This move aligns with the company's strategy to enhance operational efficiency and focus on core business activities.

Financial Impact

Apollo Life Sciences Holdings (Pty) Ltd, the deregistered subsidiary, had a minimal financial impact on Strides Pharma's consolidated performance. For the financial year ended March 31, 2025, the subsidiary reported:

The negligible revenue and negative net worth underscore the rationale behind the company's decision to deregister this non-operating entity.

Regulatory Compliance

Strides Pharma Science Limited has duly informed the stock exchanges about this development, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company received communication regarding the deregistration from its local consultant on August 25, 2025, which explains the slight delay in intimation to the stock exchanges.

Corporate Structure Optimization

This deregistration is a clear indication of Strides Pharma's commitment to optimizing its corporate structure. By eliminating non-operating entities, the company aims to reduce administrative overhead and potentially improve overall group efficiency.

The move is expected to have no material impact on Strides Pharma's operations or financial performance, given the insignificant contribution of Apollo Life Sciences Holdings to the company's consolidated financials.

As Strides Pharma Science continues to refine its global presence, investors and industry observers will be keen to see how this streamlining effort contributes to the company's long-term strategic goals and operational efficiency.